Late-onset autoimmunity: The paradigm of primary biliary cirrhosis - A mini-review

Gerontology

Volumn 54, Issue 4, 2008, Pages 193-201

  Siegel, Samuel M ^a   Selmi, Carlo ^a,b   Dottorini, Lorenzo ^b   Antelmi, Magda ^b   Zuin, Massimo ^b   Lanfredini, Mario ^c   Gershwin, M Eric ^a,d  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF MILAN   (Italy)

^c SAN PAOLO HOSPITAL   (Italy)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Antimitochondrial antibody; Autoreactivity; Immunosenescence; Tolerance

Indexed keywords

ANTIHISTAMINIC AGENT; ANTINUCLEAR ANTIBODY; AUTOANTIBODY; CALCIUM; COLCHICINE; COLESTYRAMINE; LIVER KIDNEY MICROSOME ANTIBODY; METHOTREXATE; MITOCHONDRION ANTIBODY; NALTREXONE; NEURONAL NUCLEAR ANTIBODY; NEUTROPHIL CYTOPLASMIC ANTIBODY; RIFAMPICIN; SERTRALINE; SMOOTH MUSCLE ANTIBODY; SOLUBLE LIVER ANTIGEN ANTIBODY; URSODEOXYCHOLIC ACID; VITAMIN D;

AUTOIMMUNE DISEASE; AUTOIMMUNE HEPATITIS; AUTOIMMUNE THYROIDITIS; AUTOIMMUNITY; BILE DUCT CARCINOMA; BLOOD ANALYSIS; BONE ATROPHY; BREAST CANCER; CLINICAL FEATURE; COMORBIDITY; DERMATOMYOSITIS; DISEASE COURSE; DRUG EFFICACY; ENVIRONMENTAL FACTOR; FAMILY HISTORY; FATIGUE; HEREDITY; HUMAN; HYPERCHOLESTEROLEMIA; IMMUNOBIOLOGY; IMMUNOPATHOGENESIS; IMMUNOSENESCENCE; IMMUNOSUPPRESSIVE TREATMENT; INSULIN DEPENDENT DIABETES MELLITUS; LIVER CELL CARCINOMA; LIVER FIBROSIS; LIVER GRANULOMA; LIVER TRANSPLANTATION; METABOLIC BONE DISEASE; MULTIPLE SCLEROSIS; MYASTHENIA GRAVIS; NONHUMAN; PORTAL HYPERTENSION; PREVALENCE; PRIMARY BILIARY CIRRHOSIS; PRIMARY SCLEROSING CHOLANGITIS; PRIORITY JOURNAL; PROGNOSIS; PRURITUS; RAYNAUD PHENOMENON; RECOMMENDED DRUG DOSE; RHEUMATOID ARTHRITIS; SCLERODERMA; SENESCENCE; SEROLOGY; SEX DIFFERENCE; SHORT SURVEY; SJOEGREN SYNDROME; SYSTEMIC LUPUS ERYTHEMATOSUS; SYSTEMIC SCLEROSIS; TREATMENT OUTCOME; VITAMIN D DEFICIENCY; WEIGHT BEARING;

ADULT; AGE OF ONSET; AGED; AGING; AUTOIMMUNE DISEASES; AUTOIMMUNITY; COMORBIDITY; HUMANS; LIVER CIRRHOSIS, BILIARY; MIDDLE AGED; RISK FACTORS; SEX FACTORS;

EID: 45549110088     PISSN: 0304324X     EISSN: None     Source Type: Journal    
DOI: 10.1159/000138335     Document Type: Short Survey

References (56)

1. Hakim FT, Flomerfelt FA, Boyiadzis M, Gress RE: Aging, immunity and cancer. Curr Opin Immunol 2004;16: 151-156.
2. Pawelec G, Mariani E, McLeod J, Ben-Yehuda A, Fulop T, Aringer M, Barnett Y: Engineering anticancer t cells for extended functional longevity. Ann NY Acad Sci 2004;1019:178-185.
3. Prelog M: Aging of the immune system: a risk factor for autoimmunity? Autoimmun Rev 2006;5:136-139.
4. Kaplan MM, Gershwin ME: Primary biliary cirrhosis. N Engl J Med 2005;353:1261-1273.
5. Gershwin ME, Ansari AA, Mackay IR, Nakanuma Y, Nishio A, Rowley MJ, Coppel RL: Primary biliary cirrhosis: an orchestrated immune response against epithelial cells. Immunol Rev 2000;174:210-225.
6. Selmi C, Invernizzi P, Zuin M, Podda M, Gershwin ME: Genetics and geoepidemiology of primary biliary cirrhosis: following the footprints to disease etiology. Semin Liver Dis 2005;25:265-280.
7. Kim WR, Lindor KD, Locke GR 3rd, Therneau TM, Homburger HA, Batts KP, Yawn BP, Petz JL, Melton LJ 3rd, Dickson ER: Epidemiology and natural history of primary biliary cirrhosis in a US community. Gastroenterology 2000;119:1631-1636.
8. Gershwin ME, Selmi C, Worman HJ, Gold EB, Watnik M, Utts J, Lindor KD, Kaplan MM, Vierling JM: Risk factors and comorbidities in primary biliary cirrhosis: a controlled interview-based study of 1,032 patients. Hepatology 2005;42:1194-1202.
9. Ala A, Stanca CM, Bu-Ghanim M, Ahmado I, Branch AD, Schiano TD, Odin JA, Bach N: Increased prevalence of primary biliary cirrhosis near Superfund toxic waste sites. Hepatology 2006;43:525-531.
10. Abu-Mouch S, Selmi C, Benson GD, Kenny TP, Invernizzi P, Zuin M, Podda M, Rossaro L, Gershwin ME: Geographic clusters of primary biliary cirrhosis. Clin Dev Immunol 2003;10:127-131.
11. Rieger R, Gershwin ME: The X and why of xenobiotics in primary biliary cirrhosis. J Autoimmun 2007;28:76-84.
12. Bjornsson E, Simren M, Olsson R, Chapman RW: Fatigue is not a specific symptom in patients with primary biliary cirrhosis. Eur J Gastroenterol Hepatol 2005;17:351-357.
13. Koulentaki M, Ioannidou D, Stefanidou M, Maraki S, Drigiannakis I, Dimoulios P, Melono JM, Tosca A, Kouroumalis EA: Dermatological manifestations in primary biliary cirrhosis patients: a case control study. Am J Gastroenterol 2006;101:541-546.
14. Benetti A, Crosignani A, Varenna M, Giussani CS, Allocca M, Zuin M, Podda M, Battezzati PM: Primary biliary cirrhosis is not an additional risk factor for bone loss in women receiving regular calcium and vitamin D supplementation: a controlled longitudinal study. J Clin Gastroenterol 2008;42:306-311.
15. Allocca M, Crosignani A, Gritti A, Ghilardi G, Gobatti D, Caruso D, Zuin M, Podda M, Battezzati PM: Hypercholesterolaemia is not associated with early atherosclerotic lesions in primary biliary cirrhosis. Gut 2006;55:1795-1800.
16. Rigamonti C, Shand LM, Feudjo M, Bunn CC, Black CM, Denton CP, Burroughs AK: Clinical features and prognosis of primary biliary cirrhosis associated with systemic sclerosis. Gut 2006;55:388-394.
17. Miyakawa H, Tanaka A, Kikuchi K, Matsushita M, Kitazawa E, Kawaguchi N, Fujikawa H, Gershwin ME: Detection of antimitochondrial autoantibodies in immunofluorescent AMA-negative patients with primary biliary cirrhosis using recombinant autoantigens. Hepatology 2001;34:243-248.
18. Invernizzi P, Crosignani A, Battezzati PM, Covini G, De Valle G, Larghi A, Zuin M, Podda M: Comparison of the clinical features and clinical course of antimitochondrial antibody-positive and -negative primary biliary cirrhosis. Hepatology 1997;25:1090-1095.
19. Invernizzi P, Selmi C, Ranftler C, Podda M, Wesierska-Gadek J: Antinuclear antibodies in primary biliary cirrhosis. Semin Liver Dis 2005;25:298-310.
20. Ludwig J, Dickson ER, McDonald GS: Staging of chronic nonsuppurative destructive cholangitis (syndrome of primary biliary cirrhosis). Virchows Arch A Pathol Anat Histol 1978;379:103-112.
21. Guo J, Friedman SL: Hepatic fibrogenesis. Semin Liver Dis 2007;27:413-426.
22. Friedman SL: Hepatic stellate cells: protean, multifunctional, and enigmatic cells of the liver. Physiol Rev 2008;88:125-172.
23. Harada K, Nakanuma Y: Molecular mechanisms of cholangiopathy in primary biliary cirrhosis. Med Mol Morphol 2006;39:55-61.
24. Forton DM, Patel N, Prince M, Oatridge A, Hamilton G, Goldblatt J, Allsop JM, Hajnal JV, Thomas HC, Bassendine M, Jones DE, Taylor-Robinson SD: Fatigue and primary biliary cirrhosis: association of globus pallidus magnetisation transfer ratio measurements with fatigue severity and blood manganese levels. Gut 2004;53:587-592.
25. Bergasa NV, Mehlman JK, Jones EA: Pruritus and fatigue in primary biliary cirrhosis. Baillieres Best Pract Res Clin Gastroenterol 2000;14:643-655.
26. Terg R, Coronel E, Sorda J, Munoz AE, Findor J: Efficacy and safety of oral naltrexone treatment for pruritus of cholestasis, a crossover, double blind, placebo-controlled study. J Hepatol 2002;37:717-722.
27. de Franchis R: Evolving consensus in portal hypertension. Report of the Baveno IV consensus workshop on methodology of diagnosis and therapy in portal hypertension. J Hepatol 2005;43:167-176.
28. Zein CO, Jorgensen RA, Clarke B, Wenger DE, Keach JC, Angulo P, Lindor KD: Alendronate improves bone mineral density in primary biliary cirrhosis: a randomized placebo-controlled trial. Hepatology 2005;42:762-771.
29. Allocca M, Crosignani A, Gritti A, Ghilardi G, Gobatti D, Caruso D, Zuin M, Podda M, Battezzati PM: Hypercholesterolaemia is not associated with early atherosclerotic lesions in primary biliary cirrhosis. Gut 2006;55:1795-1800.
30. Findor J, He XS, Sord J, Terg R, Gershwin ME: Primary biliary cirrhosis and hepatocellular carcinoma. Autoimmun Rev 2002;1:220-225.
31. Beuers U: Drug insight: mechanisms and sites of action of ursodeoxycholic acid in cholestasis. Nat Clin Pract Gastroenterol Hepatol 2006;3:318-328.
32. Gluud C, Christensen E: Ursodeoxycholic acid for primary biliary cirrhosis. Cochrane Database Syst Rev 2002;1:CD000551.
33. Parés A, Caballería L, Rodés J, Bruguera M, Rodrigo L, García-Plaza A, Berenguer J, Rodríguez-Martínez D, Mercader J, Velicia R: Long-term effects of ursodeoxycholic acid in primary biliary cirrhosis: results of a double-blind controlled multicentric trial. UDCA-Cooperative Group from the Spanish Association for the Study of the Liver. J Hepatol 2000;32:561-566.
34. Poupon RE, Poupon R, Balkau B: Ursodiol for the long-term treatment of primary biliary cirrhosis. The UDCA-PBC Study Group. N Engl J Med 1994;330:1342-1347.
35. Parés A, Caballería L, Rodés J: Excellent long-term survival in patients with primary biliary cirrhosis and biochemical response to ursodeoxycholic acid. Gastroenterology 2006;130:715-720.
36. Prince M, Christensen E, Gluud C: Glucocorticosteroids for primary biliary cirrhosis. Cochrane Database Syst Rev 2005;2: CD003778.
37. Combes B, Emerson SS, Flye NL, Munoz SJ, Luketic VA, Mayo MJ, McCashland TM, Zetterman RK, Peters MG, Di Bisceglie AM, Benner KG, Kowdley KV, Carithers RL Jr, Rosoff L Jr, Garcia-Tsao G, Boyer JL, Boyer TD, Martinez EJ, Bass NM, Lake JR, Barnes DS, Bonacini M, Lindsay KL, Mills AS, Markin RS, Rubin R, West AB, Wheeler DE, Contos MJ, Hofmann AF: Methotrexate (MTX) plus ursodeoxycholic acid (UDCA) in the treatment of primary biliary cirrhosis. Hepatology 2005;42:1184-1193.
38. Gong Y, Gluud C: Colchicine for primary biliary cirrhosis: a Cochrane Hepato-Biliary Group systematic review of randomized clinical trials. Am J Gastroenterol 2005;100:1876-1885.
39. Van de Water J, Gerson LB, Ferrell LD, Lake JR, Coppel RL, Batts KP, Wiesner RH, Gershwin ME: Immunohistochemical evidence of disease recurrence after liver transplantation for primary biliary cirrhosis. Hepatology 1996;24:1079-1084.
40. Williams R, Gershwin ME: How, why, and when does primary biliary cirrhosis recur after liver transplantation? Liver Transpl 2007;13:1214-1216.
41. Joshi S, Cauch-Dudek K, Heathcote EJ, Lindor K, Jorgensen R, Klein R: Antimitochondrial antibody profiles: are they valid prognostic indicators in primary biliary cirrhosis? Am J Gastroenterol 2002;97:999-1002.
42. Neuberger J, Bradwell AR: Anti-mitochondrial antibodies in primary biliary cirrhosis. J Hepatol 2002;37:712-716.
43. Wesierska-Gadek J, Penner E, Battezzati PM, Selmi C, Zuin M, Hitchman E, Worman HJ, Gershwin ME, Podda M, Invernizzi P: Correlation of initial autoantibody profile and clinical outcome in primary biliary cirrhosis. Hepatology 2006;43:1135-1144.
44. Dickson ER, Grambsch PM, Fleming TR, Fisher LD, Langworthy A: Prognosis in primary biliary cirrhosis: model for decision making. Hepatology 1989;10:1-7.
45. Oertelt S, Rieger R, Selmi C, Invernizzi P, Ansari AA, Coppel RL, Podda M, Leung PS, Gershwin ME: A sensitive bead assay for antimitochondrial antibodies: chipping away at AMA-negative primary biliary cirrhosis. Hepatology 2007;45:659-665.
46. Oertelt S, Ridgway WM, Ansari AA, Coppel RL, Gershwin ME: Murine models of primary biliary cirrhosis: comparisons and contrasts. Hepatol Res 2007;37(suppl 3):S365-S369.
47. Selmi C, Mayo MJ, Bach N, Ishibashi H, I nvernizzi P, Gish RG, Gordon SC, Wright HI, Zweiban B, Podda M, Gershwin ME: Primary biliary cirrhosis in monozygotic and dizygotic twins: genetics, epigenetics, and environment. Gastroenterology 2004; 127:485-492.
48. Selmi C, Invernizzi P, Miozzo M, Podda M, Gershwin ME: Primary biliary cirrhosis: does X mark the spot? Autoimmun Rev 2004; 3:493-499.
49. Selmi C, Gershwin ME: Bacteria and human autoimmunity: the case of primary biliary cirrhosis. Curr Opin Rheumatol 2004;16:406-410.
50. Gleicher N, Barad DH: Gender as risk factor for autoimmune diseases. J Autoimmun 2007;28:1-6.
51. Mackay IR: The etiopathogenesis of autoimmunity. Semin Liver Dis 2005;25:239-250.
52. Youinou P: B cell conducts the lymphocyte orchestra. J Autoimmun 2007;28:143-151.
53. Abbas AK, Lohr J, Knoechel B: Balancing autoaggressive and protective T cell responses. J Autoimmun 2007;28:59-61.
54. Eaton WW, Rose NR, Kalaydjian A, Pedersen MG, Mortensen PB: Epidemiology of autoimmune diseases in Denmark. J Autoimmun 2007;29:1-9.
55. Hahn BH, Grossman J, Chen W, McMahon M: The pathogenesis of atherosclerosis in autoimmune rheumatic diseases: roles of inflammation and dyslipidemia. J Autoimmun 2007;28:69-75.
56. Meda F, Zuin M, Invernizzi P, Vergani D, Selmi C: Serum autoantibodies: a road map for the clinical hepatologist. Autoimmunity 2008;41:27-34.